# The guardian of the genome meets immunotherapy: p53-based strategies

## TL;DR

This review explores the p53 protein's role in cancer and how targeting it could improve immunotherapy treatments.

## Contribution

The paper provides a comprehensive analysis of p53's regulatory mechanisms and its therapeutic potential in immunotherapy.

## Key findings

- p53 dysfunction is a major contributor to most human cancers.
- Emerging therapies are targeting p53 to enhance immunotherapy outcomes.
- p53's role in tumor evolution is critical for developing new treatment strategies.

## Abstract

Originally reported as an oncogene and currently known to be a major “genome guardian”, the p53 protein remains one of the most explored transcription factors, exhibiting variety of functions both within transcription regulation and beyond. Given that p53 dysfunction contributes to the majority of human cancers, understanding its regulatory mechanisms and therapeutic potential remains a primary research focus. This review addresses the key aspects of p53 regulation and functionality, analyses its role in tumor evolution, and provides a comprehensive analysis of current and emerging therapeutic strategies targeting the p53, with particular emphasis on immunotherapy approaches.